The Light of Life Foundation logo
  • Thyroid Cancer Awareness Month

    Thyroid Cancer Awareness Month

    Light of Life Foundation supports Thyroid Cancer Awareness Month in the month of September. Please help spread the word "CHECK YOUR NECK" for thyroid cancer. Early detection is the key to saving lives.

  • Delicious Low Iodine Recipes

    New LOL Updated Iodine Cookbook

    Thyroid Cancer diet restrictions don't mean the end of delicious food. Browse simple, healthy recipes created for patients, by patients in the Light of Life Low Iodine Cookbook.

  • Read real survival stories

    Read real survival stories

    There are over 350,000 Thyroid Cancer patients living in the US today, across every age group, gender and race. Read the real survival stories of people just like you--and submit your own.

  • You Are Not Alone

    You Are Not Alone

    Thousands of patients, caretakers, relatives and friends from all corners of the world have joined our Facebook support group to share experiences, get advice, and offer friendship online. Click here to chat now.

  • Cindy Crawford

    Cindy Crawford

    The Light of Life Foundation is proud to report Cindy Crawford has just done a PSA photo shoot for the Light of Life Foundation. We are in the process of developing a new awareness campaign. VERY EXCITING NEWS! More to come...please revisit our website soon for more details.

About the Foundation

The Light of Life Foundation was established in the spring of 1997 by Joan Shey, a patient herself. The mission of the foundation (a 501(c)(3) non-profit organization) is to improve the quality of life of thyroid cancer patients through continual education of the lay public and the medical community, and by promoting research and development to improve thyroid cancer care.

Light of Life Foundation On Thyroid Cancer Patient Symposium

Airing live April 18th from 8:30am to 2pm EST

Symposium Program

News

Eiasi is pleased to announce that LENVIMATM (lenvatinib) is now approved for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)

The incidence of thyroid cancer has steadily increased globally over the last 50 years, and as the most common endocrine malignancy, there remains a need for additional treatment options, particularly for patients with DTC whose cancer no longer responds to radioactive iodine (RAI) therapy. The most common types of thyroid cancer, papillary and follicular, are classified as differentiated thyroid cancer (DTC) and account for approximately 90 percent of all cases.


FDA Approves Natpara® (parathyroid hormone) for Injection as an Adjunct to Calcium and Vitamin D to Control Hypocalcemia in Patients with Hypoparathyroidism

BEDMINSTER, N.J. -- January 23, 2015 -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Natpara (parathyroid hormone) as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015.

View all news...